Related Experiment Video
Updated: Mar 27, 2026

Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons
Published on: April 24, 2021
BAD, a Proapoptotic Protein, Escapes ERK/RSK Phosphorylation in Deguelin and siRNA-Treated HeLa Cells
Samra Hafeez1, Mahwish Urooj1, Shamiala Saleem1
1Institute of Molecular Biology and Biotechnology and Center for Research in Molecular Medicine, the University of Lahore, Lahore, Pakistan.
Abstract:
This study has been undertaken to explore the therapeutic effects of deguelin and specific siRNAs in HeLa cells. The data provided clearly show the silencing of ERK 1/2 with siRNAs and inhibition of ERK1/2 with deguelin treatment in HeLa cells. Additionally, we are providing information that deguelin binds directly to anti-apoptotic Bcl-2, Bcl-xl and Mcl-1 in the hydrophobic grooves, thereby releasing BAD and BAX from dimerization with these proteins. This results in increased apoptotic activity through the intrinsic pathway involved in rupture of mitochondrial membrane and release of cytochrome C. Evidence for inhibition of ERK1/2 by deguelin and escape of BAD phosphorylation at serine 112 through ERK/RSK pathway has been further fortified by obtaining similar results by silencing ERK 1/2 each with specific siRNAs. Increase in BAD after treatment with deguelin or siRNAs has been interpreted to mean that deguelin acts through several alternative pathways and therefore can be used as effective therapeutic agent.
Insights
Deguelin effectively inhibits ERK1/2 and promotes apoptosis in HeLa cells by disrupting anti-apoptotic proteins. This suggests deguelin
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- The intrinsic apoptotic pathway is crucial for cell death.
- Dysregulation of apoptosis is implicated in cancer development.
- Targeting key regulatory proteins offers therapeutic potential.
Purpose of the Study:
- To investigate the therapeutic effects of deguelin and specific siRNAs in HeLa cells.
- To elucidate the molecular mechanisms underlying deguelin's action.
- To evaluate deguelin as a potential anti-cancer agent.
Main Methods:
- Utilized specific small interfering RNAs (siRNAs) for gene silencing.
- Administered deguelin to HeLa cells for treatment.
- Analyzed protein interactions and apoptotic markers.
Main Results:
- Deguelin and siRNAs effectively inhibited Extracellular signal-Regulated Kinase 1/2 (ERK1/2) in HeLa cells.
- Deguelin directly binds to anti-apoptotic proteins (Bcl-2, Bcl-xl, Mcl-1), releasing pro-apoptotic proteins (BAD, BAX).
- This interaction triggers the intrinsic apoptotic pathway, leading to mitochondrial membrane rupture and cytochrome C release.
Conclusions:
- Deguelin induces apoptosis through direct interaction with anti-apoptotic proteins and inhibition of the ERK1/2 pathway.
- Deguelin's multifaceted mechanism suggests its potential as an effective therapeutic agent.
- Further research into deguelin's alternative pathways is warranted.
More Related Videos
05:28Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
Published on: June 2, 2023
09:18Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death
Published on: December 27, 2016
Related Concept Videos
Export of Misfolded Proteins out of the ER
Regulation of the Unfolded Protein Response
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The Extrinsic Apoptotic Pathway
The Unfolded Protein Response
Negative Regulator Molecules